Literature DB >> 2157410

Dexamethasone increases neutral sphingomyelinase activity and sphingosine levels in 3T3-L1 fibroblasts.

C K Ramachandran1, D K Murray, D H Nelson.   

Abstract

The activity of neutral sphingomyelinase (EC 3.1.4.12) in a plasma membrane enriched fraction was found to be increased in dexamethasone treated cells. The elevation of sphingomyelinase activity was blocked by cycloheximide indicating that protein synthesis was required for the steroid action. Ceramidase (EC3.5.1.23) activity was unaffected by the dexamethasone treatment. Levels of sphingosine in 3T3-L1 Cells were also increased after treatment with 10(-7) M dexamethasone for 2 and 4 hours.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2157410     DOI: 10.1016/0006-291x(90)92068-b

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

Review 1.  Sphingolipid metabolites: members of a new class of lipid second messengers.

Authors:  S Spiegel; S Milstien
Journal:  J Membr Biol       Date:  1995-08       Impact factor: 1.843

2.  Betamethasone modulation of sphingomyelin hydrolysis up-regulates CTP:cholinephosphate cytidylyltransferase activity in adult rat lung.

Authors:  R K Mallampalli; S N Mathur; L J Warnock; R G Salome; G W Hunninghake; F J Field
Journal:  Biochem J       Date:  1996-08-15       Impact factor: 3.857

Review 3.  Cell regulation by sphingosine and more complex sphingolipids.

Authors:  A H Merrill
Journal:  J Bioenerg Biomembr       Date:  1991-02       Impact factor: 2.945

4.  High sphingomyelin levels induce lysosomal damage and autophagy dysfunction in Niemann Pick disease type A.

Authors:  E Gabandé-Rodríguez; P Boya; V Labrador; C G Dotti; M D Ledesma
Journal:  Cell Death Differ       Date:  2014-01-31       Impact factor: 15.828

Review 5.  Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism.

Authors:  William L Holland; Scott A Summers
Journal:  Endocr Rev       Date:  2008-05-01       Impact factor: 19.871

6.  The role of skeletal muscle sphingolipids in the development of insulin resistance.

Authors:  Marek Straczkowski; Irina Kowalska
Journal:  Rev Diabet Stud       Date:  2008-05-10

7.  Pharmacological reversion of sphingomyelin-induced dendritic spine anomalies in a Niemann Pick disease type A mouse model.

Authors:  Ana I Arroyo; Paola G Camoletto; Laura Morando; Marco Sassoe-Pognetto; Maurizio Giustetto; Paul P Van Veldhoven; Edward H Schuchman; Maria D Ledesma
Journal:  EMBO Mol Med       Date:  2014-01-21       Impact factor: 12.137

8.  Neutral sphingomyelinase in physiological and measles virus induced T cell suppression.

Authors:  Nora Mueller; Elita Avota; Lena Collenburg; Heike Grassmé; Sibylle Schneider-Schaulies
Journal:  PLoS Pathog       Date:  2014-12-18       Impact factor: 6.823

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.